Biocon Q4 Results: The pharma major's revenue from operations in the fourth quarter of FY24 stood at ₹3,917 crore, registering a rise of four per cent
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.